Efficacy of application of generic imatinib in patients with chronic myeloid leukemia
Автор: Lyamkina A.S., Autenshlyus A.I., Miroshnikov P.N., Dubrovin A.V.
Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk
Рубрика: Клинические исследования
Статья в выпуске: 2 т.32, 2017 года.
Бесплатный доступ
We have measured the residual concentration of imatinib in blood serum of patients, who have been treated with generic imatinib (Philachromin) in 24±3 hours after last administration. Patients, who have residual serum blood level of imatinib higher 900 ng/ml, have attained complete hematologic response (CHO) and major molecular response (MMR) more often, than patients, who have lower level (p
Chronic myelogenous leukemia, tyrosine kinase inhibitors imatinib concentrations
Короткий адрес: https://sciup.org/14920195
IDR: 14920195
